Why the study?
Is 1-month dual antiplatelet therapy applicable to any type of drug-eluting stent in any clinical scenario?
Is 1-month dual antiplatelet therapy applicable to any type of drug-eluting stent in any clinical scenario?
This editorial discusses the clinical applicability of very short (1-month) dual antiplatelet therapy across different drug-eluting stents and clinical scenarios to reduce bleeding complications.
the feasibility of short DAPT (3 months) after percutaneous coronary intervention (PCI) using current-generation DES in patients with HBR has been demonstrated, and is recommended in guidelines. 2,3 A current clinical question the of very short DAPT, including 1-month DAPT, in daily clinical practice. the A shorter duration of anti-platelet therapy (DAPT) is the ideal after drug-eluting stent (DES) implantation in terms of reducing the incidence of bleeding complications, although the Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent (STOPDAPT)-3 study failed to confirm the benefit of an aspirin-free strategy among patients with acute coronary syndrome (ACS) or high bleeding risk (HBR). 1 To date,
No takes yet. Share an insight, caveat, or question.
Yoshiyasu Minami (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: